Drug Profile

BMS 986446

Alternative Names: Anti-tau antibody - Prothena; BMS-986446; PRX 005

Latest Information Update: 07 Oct 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Prothena
Developer Bristol-Myers Squibb; Prothena
Class Antidementias; Monoclonal antibodies; Neuroprotectants
Mechanism of Action Tau protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Alzheimer's disease

Most Recent Events

01 Oct 2025 BMS 986446 receives Fast Track designation for Alzheimer's disease (Early-stage disease) [SC] in USA
06 May 2025 Bristol Myers Squibb plans a phase I pharmacokinetic trial (In volunteers) in USA in May 2025 (IV) (SC) (NCT06955741)
05 May 2025 Bristol-Myers Squibb initiates a phase I pharmacokinetic trial (In volunteers) in the US (IV) (NCT06955741)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com